| dc.creator | Anifandis G., Michopoulos A., Daponte A., Chatzimeletiou K., Simopoulou M., Messini C.I., Polyzos N.P., Vassiou K., Dafopoulos K., Goulis D.G. | en |
| dc.date.accessioned | 2023-01-31T07:31:56Z | |
| dc.date.available | 2023-01-31T07:31:56Z | |
| dc.date.issued | 2019 | |
| dc.identifier | 10.1080/19396368.2018.1516000 | |
| dc.identifier.issn | 19396368 | |
| dc.identifier.uri | http://hdl.handle.net/11615/70633 | |
| dc.description.abstract | Infertile couples with low oocyte yield in combination with abnormal semen parameters may experience intra-cytoplasmic sperm injection (ICSI) failure. An established factor associated with ICSI failure is oocyte activation deficiency (AOD). The latter originates from seminal contributors, such as phospholipase C-zeta (PLCζ) that is not adequate to produce calcium (Ca 2+ ) oscillations for oocyte activation. Apart from this natural activator, other stimulants, such as A23187, ionomycin, strontium chloride or even electric pulses, have been used in embryological laboratories to overcome AOD and ICSI failure. The aim of the present narrative review is to discuss the role of Ca +2 oscillations in oocyte activation and summarize the evidence concerning the use of oocyte activators as agents for artificial oocyte activation (AOA). Studies in humans and animals have emerged many physiological, pathophysiological and ethical aspects of AOA. In conclusion, in mammalian eggs, the cytosolic Ca +2 oscillations derive from a periodic release of Ca +2 from intracellular pools. PLCζ, as well as artificial stimulants, have been used to produce Ca +2 oscillations for AOA. As the latter may increase the risk of epigenetic induced malformations, further studies are required to clarify whether AOA constitutes an effective and safe method to overcome ICSI failure. Abbreviations: AOA: artificial oocyte activation; AOD: oocyte activation deficiency; Ca +2 : Calcium; CAMKII: Ca +2 /calmodulin-dependent protein kinase II; CICR: calcium-induced calcium-release; DAG: diacylglycerol; GM-CSF: granulocyte-macrophage colony-stimulating factor; ICSI: intra-cytoplasmic sperm injection; InsP 3 R: inositol-trisphosphate receptor; IP 3 : inositol 1,4,5-trisphosphate; IVF: in vitro fertilization; MAP: mitogen-activated protein; MII: metaphase II; NADP: nicotinic acid adenine dinucleotide phosphate; NO: nitric oxide; PAWP: post-acrosomal WW-binding domain protein; PIP 2 : phosphatidylinositol 4,5-bisphosphate; PLC: phospholipase C; PLCζ: phospholipase C-zeta; SOAFs: spermatozoon-released oocyte-activating factors; Sr +2 : strontium; TFF: total fertilization failure. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. | en |
| dc.language.iso | en | en |
| dc.source | Systems Biology in Reproductive Medicine | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053435001&doi=10.1080%2f19396368.2018.1516000&partnerID=40&md5=d2886bac499dcaa99e6a14facd851908 | |
| dc.subject | calcimycin | en |
| dc.subject | calcium ion | en |
| dc.subject | ionomycin | en |
| dc.subject | pawp protein | en |
| dc.subject | plc gamma protein | en |
| dc.subject | protein | en |
| dc.subject | strontium chloride | en |
| dc.subject | unclassified drug | en |
| dc.subject | calcium ionophore | en |
| dc.subject | carrier protein | en |
| dc.subject | phosphatidylinositol 4,5 bisphosphate phosphodiesterase | en |
| dc.subject | PLCZ1 protein, human | en |
| dc.subject | seminal plasma protein | en |
| dc.subject | WBP2NL protein, human | en |
| dc.subject | calcium signaling | en |
| dc.subject | cell activation | en |
| dc.subject | human | en |
| dc.subject | intracytoplasmic sperm injection | en |
| dc.subject | medical ethics | en |
| dc.subject | nonhuman | en |
| dc.subject | oocyte | en |
| dc.subject | pathophysiology | en |
| dc.subject | physiology | en |
| dc.subject | priority journal | en |
| dc.subject | Review | en |
| dc.subject | animal | en |
| dc.subject | calcium signaling | en |
| dc.subject | intracytoplasmic sperm injection | en |
| dc.subject | oocyte | en |
| dc.subject | treatment failure | en |
| dc.subject | Animals | en |
| dc.subject | Calcium Ionophores | en |
| dc.subject | Calcium Signaling | en |
| dc.subject | Carrier Proteins | en |
| dc.subject | Humans | en |
| dc.subject | Oocytes | en |
| dc.subject | Phosphoinositide Phospholipase C | en |
| dc.subject | Seminal Plasma Proteins | en |
| dc.subject | Sperm Injections, Intracytoplasmic | en |
| dc.subject | Treatment Failure | en |
| dc.subject | Taylor and Francis Ltd | en |
| dc.title | Artificial oocyte activation: physiological, pathophysiological and ethical aspects | en |
| dc.type | other | en |